Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence.

Indian pharma major Lupin announced Thursday that its wholly-owned subsidiary VISUfarma has entered an exclusive licensing ...

YUVEZZI is a carbachol and brimonidine tartrate ophthalmic solution approved by the US Food and Drug Administration (FDA) for ...

In the past month, Lupin underperformed the market by falling 9 per cent, as against a 1.4 per cent gain in the BSE Sensex and a 2.6 per cent rally in the BSE Healthcare index.

Prabhudas Lilladher recommended Accumulate rating on Lupin with a target price of Rs 2500 in its research report dated August 10, 2026.

Global pharma major Lupin Limited ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that VISUfarma B.V. ("VISUfarma"), a wholly owned subsidiary of Lupin, has ...

Lupin Ltd has received final USFDA approval for its generic Pitolisant tablets, bioequivalent to Wakix, to treat excessive ...

Lupin's first computer-generated adventures loses some of his franchise's romantic aura, but it would take more than that to steal his mojo. First conceived by the manga artist Monkey Punch (aka Katō ...

Lupin shares saw an uptick after Jefferies raised its target price and reiterated a “Buy” rating post-strong Q2 results. The ...

Lupin's VISUfarma BV has obtained exclusive rights to commercialise YUVEZZI, a presbyopia treatment, across key European ...

On Friday, a post on the official X (formerly Twitter) account for the Lupin the 3rd franchise announced a new animated movie set to come out next year. The film, tentatively titled Lupin the IIIrd ...